Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis.
Article Details
- CitationCopy to clipboard
Mowat CG, Leys D, McLean KJ, Rivers SL, Richmond A, Munro AW, Ortiz Lombardia M, Alzari PM, Reid GA, Chapman SK, Walkinshaw MD
Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis.
Acta Crystallogr D Biol Crystallogr. 2002 Apr;58(Pt 4):704-5. Epub 2002 Mar 22.
- PubMed ID
- 11914502 [ View in PubMed]
- Abstract
The product of the Rv2276 gene of Mycobacterium tuberculosis is a cytochrome P450 (P450 MT2, CYP121) which has been shown to bind tightly to a range of azole-based antifungal drugs (e.g. miconazole, clotrimazole). These drugs are potent inhibitors of mycobacterial growth, suggesting that P450 MT2 (CYP121) may be a potential drug target. The enzyme has been overexpressed in Escherichia coli and crystallized by the hanging-drop method. Crystals of P450 MT2 (CYP121) belong to the hexagonal space group P6(1)22 or P6(5)22, with unit-cell parameters a = b = 78.3, c = 265.6 A. Native data have been collected to 1.6 A resolution and Hg-derivative data to 2.5 A resolution using a synchrotron-radiation source.